logo-loader
Imugene Ltd

Imugene will present lead candidate HER-Vaxx at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about the significance of presenting the clinical stage immuno-oncology company's lead candidate - the HER-Vaxx cancer vaccine - at the upcoming American Association for Cancer Research 2019 Annual Meeting.

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Quick facts: Imugene Ltd

Price: $0.02

Market: ASX
Market Cap: $86.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

2 min read